ENHANCED INDUCTION OF LYMPHOKINE-ACTIVATED KILLER ACTIVITY FOLLOWING A SINGLE-DOSE OF CISPLATIN IN CANCER-PATIENTS

The effects of intravenous cisplatin (CDDP) administration on the gene ration of lymphokine-activated killer (LAK) activity in peripheral blo od mononuclear (PBM) cells were investigated in cancer patients. The a bility of PBM to generate LAK activity was significantly augmented 3, 5 and 7 days after a single dose, 50 mg m(-1), of CDDP injection when compared to that before injection. NK activity of PBM was not altered. The distribution of lymphocyte subsets exhibited no significant chang e following CDDP injection, except CD2(+) cells. However, the ability of monocytes in PBM to produce TNF-alpha was significantly enhanced 5 days after the drug administration, although IL1-alpha and IL1-beta pr oduction was not augmented.